Line treatment of gastric cancer/esophageal cancer BMS immunocombination therapy reaches phase 3 clinical endpoint

A metastatic gastric cancer called CheckMate-649 is designed to assess the use of Odivo (Navulyu monoanti) combined chemotherapy for PD-L1 expression-positive, or combined positive score (CPS) of 5, compared to individual chemotherapy, the company announced today. Key Phase 3 clinical studies on the first-line therapeutic effects of patients with gastroesophageal-connected cancer or esophageal adenocarcinoma reached the total end-of-life (OS) and non-progressive lifetime (PFS) of the main study;
OS benefits were also observed in all random populations.
is the first and only PD-1 inhibitor to be used in combination with chemotherapy, and both OS and PFS are superior to PD-1 inhibitors for chemotherapy alone.
study, the safety characteristics of Odivo combined chemotherapy were consistent with those of known Odivo and first-line chemotherapy for stomach and esophageal cancer.
is the fifth most common cancer in the world and the third leading cause of death.
china, stomach cancer is the second largest tumor after lung cancer, and its morbidity and mortality rate account for 44% and 50% of the global incidence and death of stomach cancer, respectively.
broad definition of stomach cancer, including gastroesophageal joint (GEJ) cancer, which forms at the junction of the stomach and esophageal, can be attributed to stomach cancer.
compared with stomach cancer, the prevalence of gastroesophageal cancer is low, but it is on the rise.
because many patients with stomach cancer are unable to withstand follow-up treatment due to the deterioration of their condition, first-line treatment is often the best chance for patients with stomach or gastroesophageal cancer to achieve results.
esophageal cancer is the seventh most common cancer in the world and the sixth leading cause of death.
Although the histological characteristics of esophageal cancer vary by region, squamous cell carcinoma and adenocarcinoma are still the two most common types, accounting for nearly 85% and 15% of the total number of esophageal cancer patients, respectively.
most people with esophageal cancer are diagnosed with advanced stages and their daily lives, including their diet, are affected.
will complete a comprehensive assessment of the available data from the CheckMate-649 study and work with the researchers to present the results at a later academic conference.
, the study and its results will also be discussed with the health administration.
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma.
this part of the study is still in the process of data maturing, hundreds of meishi Guibao blind to this data.
()